We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Ivax Launch Of Generic Neurontin Raises Eyebrows

Law360 (August 19, 2004, 12:00 AM EDT) -- Ivax Corp.’s decision Wednesday to launch a generic version of Pfizer Inc.'s blockbuster epilepsy drug Neurontin in the midst of a drawn-out patent dispute is seen by analysts as a bold but risky move.

Ivax said Wednesday that it was carrying out only a "limited" launch to a small number of buyers, most likely pharmacy-benefit managers and managed-care organizations.

Under most state pharmacy laws, Ivax's generic tablet may not technically be substitutable for Pfizer's Neurontin in the same strengths, given that it is a tablet formulation...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.